Vasodilator effects of C-type natriuretic peptide on cerebral arterioles in rats. 1997

Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
Department of Neurosurgery, Nagoya University School of Medicine, Japan.

The vasodilator effects of C-type natriuretic peptide (CNP) were investigated in isolated rat cerebral arterioles. CNP caused dose-dependent vasodilation, maximally by 10.0 +/- 2.2% at 10(-6) M. The median effective concentration (EC50) was 5.2 x 10(-10) M. In contrast, atrial natriuretic peptide and B-type natriuretic peptide, other members of the natriuretic peptide family, produced little or no vasodilation. Pretreatment with methylene blue (10(-4) M) abolished CNP-induced vasodilation, whereas pretreatment with NG-monomethyl-L-arginine or indomethacin did not inhibit vasodilation. Thus, CNP is suggested to cause significant vasodilation in cerebral arterioles via a cyclic guanosine monophosphate-dependent mechanism.

UI MeSH Term Description Entries
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001160 Arterioles The smallest divisions of the arteries located between the muscular arteries and the capillaries. Arteriole
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D020098 Natriuretic Peptide, C-Type A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified. C-Type Natriuretic Peptide,C-Type Natriuretic Peptide-22,C-Type Natriuretic Peptide-53,CNP-22,CNP-53,C Type Natriuretic Peptide,C Type Natriuretic Peptide 22,C Type Natriuretic Peptide 53,Natriuretic Peptide, C Type,Natriuretic Peptide-22, C-Type,Natriuretic Peptide-53, C-Type,Peptide, C-Type Natriuretic,Peptide-22, C-Type Natriuretic,Peptide-53, C-Type Natriuretic
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
August 1998, Neuroreport,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
May 1998, Brain research,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
July 2010, Peptides,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
February 1997, International journal of andrology,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
July 2000, The Journal of pharmacology and experimental therapeutics,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
August 1991, Endocrinology,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
January 2013, Journal of dental research,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
September 1999, British journal of pharmacology,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
November 1997, European journal of pharmacology,
Y Mori, and M Takayasu, and Y Suzuki, and M Shibuya, and J Yoshida, and H Hidaka
October 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Copied contents to your clipboard!